Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics, Singapore s MerLion Collaborate to Find Natural Bug Killers

NEW YORK, Jan. 28--Genome Therapeutics and Singapore's MerLion Pharmaceuticals have begun joint research to identify natural products with antibacterial properties, the two companies said today.

 

MerLion, which is a privately owned spinoff of the privatized Centre for Natural Product Research of the Singapore Institute of Molecular and Cell Biology, will provide a large library of natural products for screening.

 

Genome Therapeutics, which is based in Waltham, Mass., will supply its portfolio of validated pathogenic targets.

MerLion Pharma will use Genome Therapeutics assays to identify chemicals with antibacterial properties that may be valuable as drugs.

 

Research will be overseen by a joint committee from both companies.

 

The two companies will share development costs and rights to clinical development and commercialization of drug candidates.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.